The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: A multicenter phase II trial of the AGO Study Group (AGO-GYN 8).
Guenter Emons
No relevant relationships to disclose
Christian Kurzeder
No relevant relationships to disclose
Barbara Schmalfeldt
No relevant relationships to disclose
Alexander Reuss
No relevant relationships to disclose
Nikolaus de Gregorio
No relevant relationships to disclose
Jacobus Pfisterer
No relevant relationships to disclose
Tjoung-Won Park-Simon
No relevant relationships to disclose
Sven Mahner
No relevant relationships to disclose
Willibald Schroeder
No relevant relationships to disclose
Hans-Joachim Lueck
Consultant or Advisory Role - Celgene; Eisai; Novartis; Roche
Honoraria - Celgene; Eisai; Novartis; Roche
Martin Leonhard Heubner
No relevant relationships to disclose
Lars Christian Hanker
No relevant relationships to disclose
Falk Thiel
No relevant relationships to disclose
Felix Hilpert
No relevant relationships to disclose